Defence Therapeutics Inc.
DTC
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -49.85% | 94.11% | -94.67% | -67.96% | 88.80% |
| Depreciation & Amortization | -60.85% | -26.35% | 149.02% | 36.84% | 5,816.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.87% | -25.61% | -92.77% | -77.47% | 56.85% |
| Operating Income | 48.87% | 25.61% | 92.77% | 77.47% | -56.85% |
| Income Before Tax | 15.02% | 32.65% | 90.60% | 72.84% | 27.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.02% | 32.65% | 90.60% | 72.84% | 23.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.02% | 32.65% | 90.60% | 72.84% | 23.44% |
| EBIT | 48.87% | 25.61% | 92.77% | 77.47% | -56.85% |
| EBITDA | 48.55% | 26.12% | 92.91% | 77.85% | -55.29% |
| EPS Basic | 29.49% | 38.91% | 91.06% | 73.73% | 27.18% |
| Normalized Basic EPS | 34.07% | 28.99% | 91.00% | 73.82% | 31.47% |
| EPS Diluted | 29.49% | 38.91% | 91.06% | 73.73% | 27.18% |
| Normalized Diluted EPS | 34.07% | 28.99% | 91.00% | 73.82% | 31.47% |
| Average Basic Shares Outstanding | 20.23% | 10.32% | 4.76% | 3.77% | 5.29% |
| Average Diluted Shares Outstanding | 20.23% | 10.32% | 4.76% | 3.77% | 5.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |